Determining the efficacy of corneal crosslinking in progressive keratoconus.
Determining the efficacy of corneal crosslinking in progressive keratoconus.
复制标题
DOI：
10.12669/pjms.332.11690
复制
发表时间：
2017-03
影响因子：
2.2
通讯作者：
Ishaq M
中科院分区：
文献类型：
--
作者：
Malik S;Humayun S;Nayyar S;Ishaq M
目的 使用角膜地形图确定角膜交联 (CXL) 对患有进行性圆锥角膜的眼睛的疗效。这项随机对照试验于 2013 年 10 月至 2014 年 4 月在巴基斯坦拉瓦尔品第武装部队眼科研究所进行。共纳入 30 名患有双侧进行性圆锥角膜的患者的 60 只眼睛。将患者的每只眼睛随机分为治疗组（A 组）或对照未治疗组（B 组），每组 30 只眼睛。每位患者均获得书面知情同意书，然后使用局部核黄素滴眼液进行角膜交联（CXL）。术后三个月进行随访，重复并记录角膜地形图。患者的平均年龄为23.13±7.62岁（范围13至39岁）。其中男性26例，女性34例。研究开始时，A 组的平均 simK 值为 50.94±4.84 屈光度，B 组为 49.73±5.24 屈光度。三个月随访时，A 组的平均 simK 值（48.28±4.47）显着低于 B 组（51.11±4.85）。 34 只眼 (56.7%) 的圆锥角膜得到改善/保持稳定，而 26 只眼 (43.3%) 的病情出现进展。在各组之间进行比较时，A 组的有效频率显着高于 B 组（86.7% vs. 26.7%；p=.000）。在三个月的随访中，发现角膜交联可以有效地使进行性圆锥角膜患者的疾病消退或阻止疾病进展，但是，角膜交联的功效不受患者年龄和性别的影响。
To determine the Efficacy of Corneal Crosslinkage (CXL), using Corneal Topography, in eyes with progressive Keratoconus. This randomized control trial was conducted at Armed Forces Institute of Ophthalmology, Rawalpindi, Pakistan from October 2013 to April 2014. A total of 60 eyes of 30 patients were included who presented with bilateral progressive Keratoconus. Each eye of the patient was randomized either to a treatment group (Group-A) or control untreated group (Group-B) of 30 eyes each. A written informed consent was obtained from each patient, following which corneal crosslinkage (CXL) with topical riboflavin eye drops was performed. Follow up visit was done at three months post operatively, Corneal topography was repeated and recorded. The mean age of the patients was 23.13±7.62 years (range 13 to 39 years). There were 26 males and 34 females patients. The mean simK value at the start of study was 50.94±4.84 diopters in Group-A and 49.73±5.24 diopters in Group-B. At three months follow-up, the mean simK value was significantly lower in Group-A (48.28±4.47) as compared to Group-B (51.11±4.85). Keratoconus improved/ remained stable in 34 (56.7%) eyes while progressive disease was noted in 26 (43.3%) eyes. When compared between the groups, the frequency of efficacy was significantly higher in Group-A (86.7% vs. 26.7%; p=.000) as compared to Group-B. Corneal Crosslinking was found effective in causing regression or halting the progression of disease in patients with progressive Keratoconus at three months follow-up, however, the efficacy of corneal crosslinking was unaffected by patient’s age and gender.